The letter 'Local safety of repeated intravitreal Ozurdex' by Hernández-Martinez et al 1 highlights the impact of intravitreal Dexamethason-implant (Ozurdex) on lens opacification. They showed in a retrospective review that four out of five (BRVO) or six (CRVO) eyes receiving a second Ozurdex showed a progression of cataract requiring surgery. As the Geneva study has shown, 2 Ozurdex is an effective treatment option for macular edema due to RVO. While our study 3 confirms these data, it furthermore shows a significant progression in cataract formation after the third intravitreal injection. Therefore, it is mandatory to consider along with age and intraocular pressure the lens status when using intravitreal Ozurdex. In the mentioned retrospective case series by Hernández-Martinez et al, it is not clear whether there is a progression of an existing cataract to a cataract requiring surgery or clear lenses showing a beginning of cataract formation. Furthermore, no objective classification of lens opacification was assessed to show which kind of lens opacification shows a significant progression requiring surgery. It is also necessary to investigate recurrence rates, treatment intervals and the data should be supplemented by a clear follow-up time. We agree that long-term follow-up data are needed to confirm present observations. As the adequate treatment of macular edema due to RVO is still a challenge, treatment possibilities including intravitreal steroids, anti-VEGF substances, laser photocoagulation or combinations are safe and effective options after taking into account the pathogenesis of retinal vein occlusion.
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The author declares no conflict of interest. used to assess failure and complications after deep sclerectomy with mitomycin C in eyes with failed glaucoma surgery, pseudophakia, or both. He pointed out that these events had occurred at unknown times before the visit at which they were recorded, making the survival curves too good, and recommended that interval censoring 3 adjust for this bias. However, competing risk bias should additionally be considered. Drs Anand and Wechsler operated on 82 patients, 2 who were on average 76 years old. A total of 20 patients died during the over 5-year-long observation period. 2 The authors do not mention how they dealt statistically with patients who died. 2 We dare expect they were censored just like the patients who became too ill to attend their clinic. 2 However, a fundamental difference exists between these two groups: only the latter group of patients remained at risk after censoring.
After censoring, the Kaplan-Meier curve will drop proportionately more with any subsequent event as compared with what it would have dropped had censoring not taken place. A key assumption is that censoring is independent of the risk of experiencing the event of interest, that is, the risk is equal before and after censoring. 4 Clearly, this assumption is not met if any subjects die: the survival curve will become too pessimistic. Death is a competing risk event, which should be dealt with methods other than censoring, 5, 6 such as cumulative incidence analysis, 7 found both in the 
